Schnell R - Search Results

1

Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.

Schnell R, Dietlein M, Schomäcker K, Kobe C, Borchmann P, Schicha H, Hallek M, Engert A. Schnell R, et al. Onkologie. 2008 Feb;31(1-2):49-51. doi: 10.1159/000111758. Epub 2008 Jan 22. Onkologie. 2008. PMID: 18268399

2

Imaging of central nervous system lymphomas with iodine-123 labeled rituximab.

Dietlein M, Pels H, Schulz H, Staak O, Borchmann P, Schomäcker K, Fischer T, Eschner W, Pogge von Strandmann E, Schicha H, Engert A, Schnell R. Dietlein M, et al. Among authors: schnell r. Eur J Haematol. 2005 Apr;74(4):348-52. doi: 10.1111/j.1600-0609.2004.00401.x. Eur J Haematol. 2005. PMID: 15777348

3

Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.

Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, Eschner W, Hansen H, Morschhauser F, Schicha H, Diehl V, Raubitschek A, Engert A. Schnell R, et al. J Clin Oncol. 2005 Jul 20;23(21):4669-78. doi: 10.1200/JCO.2005.09.098. J Clin Oncol. 2005. PMID: 16034043

4

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).

Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M. Schulz H, et al. Among authors: schnell r. Blood. 2008 Jan 1;111(1):109-11. doi: 10.1182/blood-2007-03-078725. Epub 2007 Oct 15. Blood. 2008. PMID: 17938252 Free article. Clinical Trial.

5

[Hodgkin's lymphoma in nuclear medicine: diagnostic and therapeutic aspects].

Staak JO, Dietlein M, Engert A, Weihrauch MR, Schomäcker K, Fischer T, Eschner W, Borchmann P, Diehl V, Schicha H, Schnell R. Staak JO, et al. Among authors: schnell r. Nuklearmedizin. 2003 Feb;42(1):19-24. Nuklearmedizin. 2003. PMID: 12601450 Review. German.

6

[Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan. Clinical considerations, radiopharmacy, radiation protection, perspectives].

Schomäcker K, Dietlein M, Schnell R, Pinkert J, Eschner W, Zimmermanns B, Fischer T, Engert A, Schicha H. Schomäcker K, et al. Among authors: schnell r. Nuklearmedizin. 2005;44(4):166-77. doi: 10.1267/nukl05040166. Nuklearmedizin. 2005. PMID: 16163413 German.

7

A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.

Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V, Engert A. Schnell R, et al. Clin Cancer Res. 2002 Jun;8(6):1779-86. Clin Cancer Res. 2002. PMID: 12060617 Clinical Trial.

8

The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.

Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Staak O, Zhang HF, Davis T, Keler T, Diehl V, Graziano RF, Engert A. Borchmann P, et al. Among authors: schnell r. Blood. 2003 Nov 15;102(10):3737-42. doi: 10.1182/blood-2003-02-0515. Epub 2003 Jul 24. Blood. 2003. PMID: 12881320 Free article.

9

Monoclonal antibody-based immunotherapy of Hodgkin's lymphoma.

Borchmann P, Schnell R, Schulz H, Engert A. Borchmann P, et al. Among authors: schnell r. Curr Opin Investig Drugs. 2004 Dec;5(12):1262-7. Curr Opin Investig Drugs. 2004. PMID: 15648946 Review.

10

The role of pixantrone in the treatment of non-Hodgkin's lymphoma.

Borchmann P, Schnell R. Borchmann P, et al. Among authors: schnell r. Expert Opin Investig Drugs. 2005 Aug;14(8):1055-61. doi: 10.1517/13543784.14.8.1055. Expert Opin Investig Drugs. 2005. PMID: 16050797 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

319 results

Search Page

Filters